Kevin Noonan is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s biotechnology and pharmaceuticals practice group.
NIST Proposes Clarifications to Bayh-Dole March-in Rights Regulations
Proposed changes to rules governing the commercialization of technologies developed with federal funding prompts significant stakeholder feedback.
The NIST Proposes Clarifications to Bayh-Dole March-in Rights Regulations
Patenting Prospects for Cell-Based Therapies
Cell-based therapies are moving medical treatments forward, but intellectual property uncertainties may delay progress.